Literature DB >> 22137796

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Madhavi Challa-Malladi1, Yen K Lieu, Olivia Califano, Antony B Holmes, Govind Bhagat, Vundavalli V Murty, David Dominguez-Sola, Laura Pasqualucci, Riccardo Dalla-Favera.   

Abstract

We report that diffuse large B cell lymphoma (DLBCL) commonly fails to express cell-surface molecules necessary for the recognition of tumor cells by immune-effector cells. In 29% of cases, mutations and deletions inactivate the β2-Microglobulin gene, thus preventing the cell-surface expression of the HLA class-I (HLA-I) complex that is necessary for recognition by CD8(+) cytotoxic T cells. In 21% of cases, analogous lesions involve the CD58 gene, which encodes a molecule involved in T and natural killer cell-mediated responses. In addition to gene inactivation, alternative mechanisms lead to aberrant expression of HLA-I and CD58 in >60% of DLBCL. These two events are significantly associated in this disease, suggesting that they are coselected during lymphomagenesis for their combined role in escape from immune-surveillance.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137796      PMCID: PMC3660995          DOI: 10.1016/j.ccr.2011.11.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  49 in total

1.  Prediction of deleterious human alleles.

Authors:  S Sunyaev; V Ramensky; I Koch; W Lathe; A S Kondrashov; P Bork
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

2.  The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.

Authors:  James Z Huang; Warren G Sanger; Timothy C Greiner; Louis M Staudt; Dennis D Weisenburger; Diane L Pickering; James C Lynch; James O Armitage; Roger A Warnke; Ash A Alizadeh; Izidore S Lossos; Ronald Levy; Wing C Chan
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

4.  Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system.

Authors:  Ekaterina S Jordanova; Sietske A Riemersma; Katja Philippo; Ed Schuuring; Philip M Kluin
Journal:  Int J Cancer       Date:  2003-01-20       Impact factor: 7.396

5.  Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.

Authors:  S A Riemersma; E S Jordanova; R F Schop; K Philippo; L H Looijenga; E Schuuring; P M Kluin
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

6.  The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.

Authors:  F Rosa; H Berissi; J Weissenbach; L Maroteaux; M Fellous; M Revel
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

7.  Analysis of the coding genome of diffuse large B-cell lymphoma.

Authors:  Laura Pasqualucci; Vladimir Trifonov; Giulia Fabbri; Jing Ma; Davide Rossi; Annalisa Chiarenza; Victoria A Wells; Adina Grunn; Monica Messina; Oliver Elliot; Joseph Chan; Govind Bhagat; Amy Chadburn; Gianluca Gaidano; Charles G Mullighan; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2011-07-31       Impact factor: 38.330

8.  Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Authors:  Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra
Journal:  Nature       Date:  2011-07-27       Impact factor: 49.962

9.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

10.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  177 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.

Authors:  Lizalynn M Dias; Venkata Thodima; Julia Friedman; Charles Ma; Asha Guttapalli; Geetu Mendiratta; Imran N Siddiqi; Sergei Syrbu; R S K Chaganti; Jane Houldsworth
Journal:  Leuk Lymphoma       Date:  2015-11-16

3.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors:  Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal:  Cancer Immunol Res       Date:  2019-06-24       Impact factor: 11.151

Review 4.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

5.  Genetics of follicular lymphoma transformation.

Authors:  Laura Pasqualucci; Hossein Khiabanian; Marco Fangazio; Mansi Vasishtha; Monica Messina; Antony B Holmes; Peter Ouillette; Vladimir Trifonov; Davide Rossi; Fabrizio Tabbò; Maurilio Ponzoni; Amy Chadburn; Vundavalli V Murty; Govind Bhagat; Gianluca Gaidano; Giorgio Inghirami; Sami N Malek; Raul Rabadan; Riccardo Dalla-Favera
Journal:  Cell Rep       Date:  2014-01-02       Impact factor: 9.423

6.  RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Authors:  A Chanut; F Duguet; A Marfak; A David; B Petit; M Parrens; S Durand-Panteix; M Boulin-Deveza; N Gachard; I Youlyouz-Marfak; D Bordessoule; J Feuillard; N Faumont
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

7.  Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Authors:  Michael Boice; Darin Salloum; Frederic Mourcin; Viraj Sanghvi; Rada Amin; Elisa Oricchio; Man Jiang; Anja Mottok; Nicolas Denis-Lagache; Giovanni Ciriello; Wayne Tam; Julie Teruya-Feldstein; Elisa de Stanchina; Wing C Chan; Sami N Malek; Daisuke Ennishi; Renier J Brentjens; Randy D Gascoyne; Michel Cogné; Karin Tarte; Hans-Guido Wendel
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

8.  Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.

Authors:  Marie Tosolini; Christelle Algans; Frédéric Pont; Bernard Ycart; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

Review 9.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

Review 10.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.